Drug Profile
Research programme: influenza virus transcriptase inhibitors - Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator ViroPharma
- Class
- Mechanism of Action DNA-directed RNA polymerase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 22 Apr 1999 Preclinical development for Influenza virus infections in USA (Unknown route)